Treatment with the immunotherapy atezolizumab extended disease-free survival (DFS) in patients with resected, early-stage non-small cell lung cancer (NSCLC), particularly those positive for the immune checkpoint protein PD-L1, according to new research to be presented at the 2021 ASCO Annual Meeting. The findings open the door to delaying recurrence even longer for patients with early-stage disease.

When compared to anti-PD-1 monotherapy, two immunotherapy agents blocking different checkpoints extended time to disease progression for patients with previously untreated, unresectable, or metastatic melanoma, new research found.

Reduced levels of screening for prostate cancer using prostate-specific antigen (PSA) testing correspond with recent increases in the diagnosis of metastatic disease, according to a study that will be presented at the 2021 ASCO Genitourinary Cancers Symposium, taking place virtually February 11-13.

During the peak of the COVID-19 pandemic, fewer Black and Hispanic patients with cancer used telehealth (including phone encounters and video visits) as compared with white patients according to findings from an analysis of data from New York City hospitals. Significant disparities in the use of telehealth not only limit access to quality cancer care for these patients during the pandemic but will continue to hinder patient care as telehealth use becomes more integrated into standard cancer care. The study will be presented as part of the virtual 2020 ASCO Quality Care Symposium. 

The study will be presented at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place virtually October 9–10, 2020.

Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study provide real world evidence to support recent clinical trial data that demonstrate a role for olaparib (Lynparza) in the treatment of advanced prostate and pancreatic cancers with BRCA1/2 inactivating mutations.

Researchers have developed an algorithm to identify molecular targets and pair them with targeted therapies for relapsed pediatric cancers with a poor prognosis. In a recent study, this approach extended the time until disease progression by three months for a small group of pediatric patients with very high-priority targets.